Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991254 | 1.00 | GPR119 (0.44) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| Hydrochloric Acid SCHEMBL30991239 | 0.99 | GPR119 (0.43) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| Hydrochloric Acid SCHEMBL21645371 | 0.99 | GPR119 (0.43) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| SCHEMBL31656637 | 0.78 | GPR119 (0.44) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| SCHEMBL2550744 | 0.77 | GPR119 (0.56) | GPR119TRPC3TRPC6CHEK1CHEK2 | |
| SCHEMBL24242875 | 0.76 | GPR119 (0.51) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| SCHEMBL18855893 | 0.76 | GPR119 (0.47) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| SCHEMBL18855597 | 0.76 | GPR119 (0.47) | GPR119TRPC3TRPC6CHEK1KCNH2 | |
| SCHEMBL23481155 | 0.73 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL23924451 | 0.72 | GPR119 (0.53) | GPR119TRPC3TRPC6CHEK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999726-B2 | 5-methyl-4-fluoro-thiazol-2-yl compounds | ELI LILLY AND COMPANY | 2024-06-04 | — | — | US | disclosed |
| EP-3829716-B1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3829716-B1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20210323958-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY | 2021-10-21 | — | — | US | disclosed |
| US-20210323958-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY | 2021-10-21 | — | — | US | disclosed |
| EP-3829716-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | Eli Lilly and Company (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112469476-A | 5-methyl-4-fluoro-thiazol-2-yl compounds | 伊莱利利公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2020028115-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028115-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323958-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | MAPT, PSEN2, PSEN1 | GPR119 316/4885TRPC3 3196/4885TRPC6 2339/4885 |
| US-11999726-B2 | 5-methyl-4-fluoro-thiazol-2-yl compounds | MAPT, PSEN2, PSEN1 | GPR119 316/4885TRPC3 3196/4885TRPC6 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.